Key Highlights
- Shares reached a 52-week bottom at $60.54, reflecting a year-to-date decline of approximately 36%
- Stifel reduced its price objective from $90 down to $85 based on electrophysiology procurement data before Q1 2026 results
- First-quarter 2026 financial results scheduled for release on April 22, 2026
- Several Wall Street firms continue recommending Buy/Outperform despite reduced price objectives — RBC maintains $115 target, UBS at $105
- InvestingPro identifies BSX among Most Undervalued stocks with Fair Value estimate of $76.66
Shares of Boston Scientific have experienced significant turbulence throughout 2026. The medical device manufacturer saw its stock price sink to a 52-week bottom of $60.54 on April 21, with current trading levels hovering between $60.43 and $60.99 — dramatically lower than the 52-week peak of $109.50.
Boston Scientific Corporation, BSX
This represents approximately a 36% year-to-date decline, wiping out considerable value from the company’s $90.6 billion market capitalization.
Analyst Rick Wise from Stifel reduced his price objective on BSX to $85 from a previous $90 in anticipation of the company’s first-quarter 2026 financial release, scheduled for April 22, 2026. However, he maintained his Buy recommendation.
The adjustment stemmed from monthly electrophysiology (EP) hospital procurement metrics that Stifel monitors to gauge quarterly performance before official earnings announcements.
January figures showed approximately 92% completion in reporting, February registered around 85%, while March data stood at roughly 60% — providing an incomplete yet significant window into EP revenue performance.
According to this dataset, Stifel projects BSX’s Q1 domestic EP consensus revenue estimate of approximately $587 million falls “within the band of achievability.” While not particularly enthusiastic, this assessment doesn’t signal alarm.
Stifel conducted a comparative analysis with Johnson & Johnson and Abbott Laboratories, utilizing the identical EP procurement database to validate projected versus realized revenues. The firm had previously identified potential shortfall risks to US EP consensus figures ahead of the last quarter using comparable methodology.
Wall Street Price Objectives Remain Significantly Higher
Notwithstanding the negative market momentum, Wall Street analysts haven’t turned bearish. Truist Securities maintained its Buy recommendation while trimming its objective to $90 from $92. The firm anticipates the cardiovascular division will deliver growth between 8.5% and 9% in the forthcoming report.
RBC Capital reaffirmed an Outperform designation with a $115 price objective following direct conversations with BSX management regarding expansion opportunities.
UBS retained its Buy recommendation and $105 target after reviewing CHAMPION-AF trial findings for the Watchman cardiac implant. The clinical trial achieved all primary and secondary endpoints — a favorable result that UBS believes mitigates headline concerns.
However, there’s a complication. The Watchman device demonstrated a marginally elevated ischemic stroke rate when compared to non-vitamin K antagonist oral anticoagulants (NOACs), which disappointed certain market participants.
Piper Sandler preserved its Overweight stance following input from a high-volume electrophysiologist who anticipates increased Watchman adoption despite the stroke data.
Shares Identified as Trading Below Fair Value
InvestingPro has designated BSX among its most undervalued equities, establishing its Fair Value at $76.66 — approximately 27% higher than current trading levels.
Revenue expansion has stayed robust, with BSX recording nearly 20% growth throughout the last twelve months. Fundamentally, this doesn’t represent a deteriorating operation — rather, it’s equity facing market headwinds.
Market attention now shifts to April 22, when BSX delivers Q1 2026 financial results. This earnings announcement will serve as the initial concrete verification of whether EP revenue performance held steady as Stifel’s procurement data indicates it potentially did.
